Biolife Sciences (Biolife Sciences) Debt-to-Asset : 0.94 (As of May. 2008)

View and export this data going back to 2005. Start your Free Trial

What is Biolife Sciences Debt-to-Asset?

Biolife Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2008 was $2.44 Mil. Biolife Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2008 was $0.42 Mil. Biolife Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in May. 2008 was $3.04 Mil. Biolife Sciences's debt to asset for the quarter that ended in May. 2008 was 0.94.

Biolife Sciences Debt-to-Asset Historical Data

The historical data trend for Biolife Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolife Sciences Debt-to-Asset Chart

Biolife Sciences Annual Data

Trend

Nov04

Nov05

Nov06

Nov07

Debt-to-Asset

0.20

0.70

0.76

0.71

Biolife Sciences Quarterly Data
	Nov04	Feb05	May05	Aug05	Nov05	Feb06	May06	Aug06	Nov06	Feb07	May07	Aug07	Nov07	Feb08	May08
Debt-to-Asset	Get a 7-Day Free Trial										0.74	0.71	0.71	0.79	0.94

Competitive Comparison of Biolife Sciences's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Biolife Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolife Sciences's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolife Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biolife Sciences's Debt-to-Asset falls into.

Biolife Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biolife Sciences's Debt-to-Asset for the fiscal year that ended in Nov. 2007 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.454	+	0.206)	/	3.762
	=	0.71

Biolife Sciences's Debt-to-Asset for the quarter that ended in May. 2008 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.437	+	0.421)	/	3.041
	=	0.94

Biolife Sciences (OTCPK:BLFE) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biolife Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biolife Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolife Sciences (Biolife Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolife Sciences Inc (OTCPK:BLFE) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2831 Street Rose Parkway, No. 200, Henderson, NV, USA, 89052

Website

https://www.biolifesciences.com

Biolife Sciences Inc is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. The company's technologies include antimicrobial copper air filters and copper-infused textiles. Its revenues are primarily generated from the sale of sanitation products.

Executives

Arthur Viola

director, 10 percent owner, officer: CEO

Biolife Sciences (Biolife Sciences) Headlines

From GuruFocus

Rhino Novi Announces Name Change and New CEO

By Marketwired Marketwired • 09-15-2020